

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation

先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL RESULTS ANNOUNCEMENT AND ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

Reference is made to the annual results announcement of LifeTech Scientific Corporation (先健科技公司) (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended 31 December 2023 (the “**Annual Results Announcement**”) and the annual report of the Company for the year ended 31 December 2023 (the “**Annual Report**”). Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Annual Results Announcement and Annual Report.

This announcement is made by the Company to provide supplemental information to note 11 to the audited consolidated financial statements of the Group for the year ended 31 December 2023 on page 18 of the Annual Results Announcement and note 25 to the audited consolidated financial statements of the Group for the same period on page 128 of the Annual Report in relation to the advance to the employees in the amount of RMB282,537,000 (“**Advance to Employees**”).

The Advance to Employees represents deferred payment from employees of the Group who acquired 230,945,000 shares under the 2019 Share Award Scheme for a purchase price of HKD1.35 per share. None of these employees is a connected person of the Company as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

As disclosed under the “2019 Share Award Scheme” section of the Annual Report, on 29 September 2020, a total of 312,620,000 shares have been vested to certain employees of the Group, among which 81,675,000 shares have been taken up by such employees. As at 1 January 2023, there was a total of 230,945,000 outstanding shares.

As at 31 December 2023, the employees acquired all 230,945,000 outstanding shares, and pending the payment of the purchase price of HKD1.35 per share, such shares were held by the 2019 Scheme Trustee on behalf of the relevant employees. Pursuant to the conditions accepted by these employees and with the consent of the Company, the ownership of such shares has been transferred to these employees and they are obliged to pay for such shares and complete the taking up of such shares within the remaining life of the 2019 Share Award Scheme.

Save as disclosed above, all other information in the Annual Results Announcement and Annual Report remains unchanged.

By Order of the Board
LifeTech Scientific Corporation
XIE Yuehui
*Executive Director, Chairman and
Chief Executive Officer*

Hong Kong, 5 July 2024

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.